This 2019 study investigated the therapeutic potential of methylene blue (MB) in a rat model of trinitrobenzene sulfonic acid (TNBS)-induced colitis, simulating ulcerative colitis. MB was administered intraperitoneally at doses of 1, 2, and 4 mg/kg, compared to a control group receiving sulfasalazine (500 mg/kg orally). MB treatment resulted in
